Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GATOR: Oral Terameprocol in Recurrent High Grade Glioma
NCT02575794Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2018
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of terameprocol in high-grade glioma (HGG), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose, Terameprocol Tumor to Plasma Concentration Ratio and 1 more. Started May 2018; status: completed.
02
Drugs
terameprocol
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02575794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575794.